“While our group carefully considered your application, I regret to inform you that you were not selected this year to serve as a committee volunteer.” When the email arrived, gently delivering the news that my application to volunteer with the ACR on a committee had not been accepted, my initial reaction was to dismiss it…
In this case report, a patient with voriconazole-induced periostitis exhibits classic symptoms & elevated ALP levels, which quickly resolve following the discontinuation of voriconazole.
The 2024 Rheumatology Research Workshop facilitated educational and relationship-building experiences for early-career and established rheumatology professionals alike.
Marko Radic, PhD, & Georg Schett, MD, were awarded the 2024 Lupus Insight Prize for advances in CAR-T cell therapy.
The organization is supporting multiple bills and initiatives to protect and expand rheumatology care in the state.
A new guideline, the 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis, is being introduced at ACR Convergence 2024 on Monday, Nov. 18. In the session, Lisa Sammaritano, MD, professor of clinical medicine at Weill Cornell Medicine and Hospital for Special Surgery, New York, will discuss the guideline development process and…
Hosted by Jonathan S. Hausmann, MD, a pediatric and adult rheumatologist at Boston Children’s Hospital and Beth Israel Deaconess Medical Center, and an instructor in medicine at Harvard Medical School, ACR on Air debuted in 2019. In this episode, ACR Master (2016) Philip J. Mease, MD, joins Dr. Hausmann for a deep dive into psoriatic…
Celebrating its long history, the Division of Rheumatology & Immunology at Medical University of South Carolina has made strides in scleroderma, lupus and more.
An engaging mix of new and returning programming is planned for ACR Convergence in Washington, D.C. “ACR Convergence is unique because of the blend of high-quality science, updates on advances in clinical care and networking opportunities to advance the field of rheumatology,” says Annual Meeting Planning Committee (AMPC) Chair Gregory C. Gardner, MD, MACP. “We…
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.